Goldman Sachs Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Richard Law initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and a price target of $24.

April 02, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Olema Pharmaceuticals with a Buy rating and set a price target of $24.
The initiation of coverage by a major financial institution like Goldman Sachs, especially with a Buy rating and a significant price target, is typically seen as a positive signal to the market. This can lead to increased investor interest and potentially drive the stock price up in the short term, as it reflects confidence in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100